

COMMENTARY

United we stand: Double targeting of CD79B and CD20 in diffuse large B-cell lymphoma

 Chiara Tarantelli¹ | Francesco Bertoni^{1,2}
¹Faculty of Biomedical Sciences, Institute of Oncology Research, Bellinzona, Switzerland

²Department of Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland

Correspondence

Francesco Bertoni, Institute of Oncology Research, via Francesco Chiesa 5, 6500 Bellinzona, Switzerland.

Email: francesco.bertoni@ior.usi.ch

Summary

Polatuzumab vedotin is antibody-drug conjugate (ADC) targeting CD79B approved for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma when given in combination with bendamustine and rituximab. The report by Kawasaki et al. provide hints on what might be happening in lymphoma cells exposed to polatuzumab vedotin and to rituximab and on potential mechanism of resistance to the ADC.

Commentary on: Kawasaki et al. The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma. *Br J Haematol* 2022;199:245-255.

KEY WORDS

antibody-drug conjugate, lymphoma, MMAE, polatuzumab vedotin, resistance, rituximab

In their paper, Kawasaki et al.¹ report on the molecular mechanisms potentially sustaining the benefit of adding the anti-CD20 monoclonal antibody rituximab to polatuzumab vedotin, increasing the anti-tumour activity of the latter in diffuse large B-cell lymphoma (DLBCL) cells.

Polatuzumab vedotin is an antibody-drug conjugate targeting CD79B based on a humanised immunoglobulin G1 monoclonal antibody, a maleimidocaproyl-valine-citrulline-*p*-aminobenzyloxycarbonyl (mc-vc-PABC) protease-cleavable peptide as linker, and the microtubule-disrupting anti-mitotic agent monomethyl auristatin E (MMAE), belonging to the class of auristatins, as payload.²

Based on a phase IB/II trial evaluating the combination of the antibody-drug conjugate with bendamustine and rituximab for patients with relapsed or refractory follicular lymphoma or DLBCL,³ multiple regulatory agencies (including the United States Food and Drug Administration, the European Medicines Agency, the British National Institute for Health and Care Excellence and SwissMedic) have approved or recommended polatuzumab vedotin for the treatment of adult patients with

relapsed/refractory DLBCL, not otherwise specified, after at least two prior therapies. With a median follow-up of 4 years, compared to bendamustine/rituximab, polatuzumab vedotin/bendamustine/rituximab achieved higher overall response rate (63% vs. 25%), higher complete response (53% vs. 23%), longer median progression-free survival (9.2 vs. 3.7 months) and longer median overall survival (12.4 vs. 4.7 months).³

The CD79B targeting antibody-drug conjugate has entered phase III trials for various patients' populations. Results have already been published for the POLARIX study, a phase III trial that compared the standard R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) against the pola-R-CHP regimen (polatuzumab vedotin instead of the tubulin-targeting agent vincristine) in 879 treatment-naïve patients with DLBCL.⁴ Patients treated with pola-R-CHP showed improved 2-year progression-free survival (study primary end-point) versus those treated with the standard R-CHOP (77% vs. 70% for a hazard ratio of 0.73).⁴ To date, no improvement on overall survival has been observed (89% at 2 years for both groups).⁴

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. *British Journal of Haematology* published by British Society for Haematology and John Wiley & Sons Ltd.

Kawasaki et al.¹ explored possible mechanisms of resistance to polatuzumab vedotin in a panel of DLBCL cell lines.¹ The mechanism of action of antibody-drug conjugates requires different steps to reach an anti-tumour effect: binding to its target on the cell surface, internalisation of the compound, release of the payload and engagement of the latter with its intracellular target and the cellular response to it (e.g., G2/M arrest and apoptosis for anti-mitotic agents like MMAE). Thus, not surprisingly, Kawasaki et al.¹ identified three factors that can affect the sensitivity of lymphoma cells toward the CD79B targeting antibody-drug conjugate and that could be active in the clinical context as well: low CD79B surface expression, high expression of ATP binding C cassette (ABC) transporters (multidrug resistance pumps), and high expression of the anti-apoptotic protein Bcl-xL (BCL2L1).¹ More importantly, the Authors noticed that, when exposed to polatuzumab vedotin, some DLBCL cell lines resistant to the antibody-drug conjugate upregulate CD20 expression levels with an increased sensitivity to rituximab, in terms of complement mediated cytotoxicity and antibody-dependent cellular cytotoxicity.¹ Involving both AKT and ERK signalling, this phenomenon, to be confirmed also in polatuzumab vedotin sensitive cell lines, can lead to benefit when adding polatuzumab vedotin to an anti-CD20 monoclonal antibody.¹ These results at least partially sustain the clinical activity seen in the phase II trial exploring the combination of polatuzumab vedotin with rituximab in relapsed or refractory patients with B-cell lymphoma,⁵ although the lack of control arms with the single agent polatuzumab vedotin makes difficult to extrapolate the exact clinical advantage given by the addition of the anti-CD20 monoclonal antibody.

Upregulation of CD20 expression after exposure to antibody-drug conjugates, with potential benefit of the combination, has been observed for compounds other than polatuzumab vedotin, suggesting that the mechanism described here might not be specific of CD79B.⁶ Anti-CD20 monoclonal antibodies are part of almost any regimen for B-cell lymphomas, and trials exploring antibody-drug conjugates are not an exception.^{7–10} As the anti-tumour activity of antibody-drug conjugates requires different steps and as the anti-CD20 monoclonal antibodies have potential mechanism of actions, the data presented by Kawasaki et al.¹ provide hints on the potential mechanisms of resistance to polatuzumab vedotin as single agent and also on what might be happening in polatuzumab vedotin-resistant lymphoma cells when exposed to compounds belonging to these two classes of agents.

ACKNOWLEDGEMENT

Open access funding provided by Universita della Svizzera italiana.

CONFLICT OF INTEREST

Francesco Bertoni: institutional research funds from ADC Therapeutics, Bayer AG, Cellestia, Helsinn, ImmunoGen, Menarini Ricerche, NEOMED Therapeutics I, Nordic Nanovector ASA, Oncternal Therapeutics; consultancy fee from Helsinn, Menarini; expert statements provided to HTG; travel grants from Amgen, Astra Zeneca, Jazz Pharmaceuticals. Chiara Tarantelli has nothing to disclose.

REFERENCES

1. Kawasaki N, Nishito Y, Yoshimura Y, Yoshiura S. The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B-cell lymphoma. *Br J Haematol.* 2022; 199:245–255.
2. Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, et al. Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. *Blood.* 2009;114(13):2721–9.
3. Sehn LH, Hertzberg M, Opat S, Herrera AF, Assouline S, Flowers CR, et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. *Blood Adv.* 2022;6(2):533–43.
4. Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trneny M, Sharman JP, et al. Polatuzumab Vedotin in previously untreated diffuse large B-cell lymphoma. *N Engl J Med.* 2022;386(4):351–63.
5. Morschhauser F, Flinn IW, Advani R, Sehn LH, Diefenbach C, Kolibaba K, et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). *Lancet Haematol.* 2019;6(5):e254–e265.
6. Gaudio E, Tarantelli C, Spriano F, Guidetti F, Sartori G, Bordone R, et al. Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models. *Haematologica.* 2020;105(11):2584–91.
7. Dang NH, Ogura M, Castaigne S, Fayad LE, Jerkeman M, Radford J, et al. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. *Br J Haematol.* 2018;182(4):583–6.
8. Linhares Y, Gandhi MD, Chung M, Adeleye J, Ungar D, Hamadani M. Safety and antitumor activity study evaluating Loncastuximab Tesirine and rituximab versus Immunochemotherapy in diffuse large B-cell lymphoma. *Blood.* 2020;136(Supplement 1):9–10.
9. Gritti G, Marlton P, Phillips TJ, Arthur C, Bannerji R, Corradini P, et al. Polatuzumab Vedotin plus Venetoclax with rituximab in relapsed/refractory diffuse large B-cell lymphoma: primary efficacy analysis of a phase Ib/II study. *Blood.* 2020;136(Supplement 1):45–7.
10. Levy MY, Jagadeesh D, Grudeva-Popova Z, Trněný M, Jurczak W, Pylypenko H, et al. Safety and efficacy of CD37-targeting Naratuximab Emtansine PLUS rituximab in diffuse large B-cell lymphoma and other NON-Hodgkin'S B-cell lymphomas - a phase 2 study. *Blood.* 2021;138(Supplement 1):526–6.

How to cite this article: Tarantelli C, Bertoni F. United we stand: Double targeting of CD79B and CD20 in diffuse large B-cell lymphoma. *Br J Haematol.* 2022;199(2):169–170. <https://doi.org/10.1111/bjh.18384>